STAGE IV LUNG CANCER AJCC V8

This early-phase study is testing a personalized vaccine made from each patient's unique tumor mutations. The goal is to see if it is safe and can help the immune system fight advanced breast cancer, melanoma, and non-small cell lung cancer. About 25 adults whose cancers have spr…

This early-phase study tests whether adding low-dose IL-2 to the immunotherapy drug pembrolizumab can strengthen the immune system's attack on advanced lung cancer. About 15 people with untreated stage IV non-small cell lung cancer will receive the combination. The main goal is t…

This study looks at whether adding chemotherapy to immunotherapy (pembrolizumab) helps older adults (70+) with advanced non-small cell lung cancer live longer compared to immunotherapy alone. About 304 participants will receive either the combination or just immunotherapy. The go…

This early-stage trial tests a new drug (MRX-2843) combined with a standard treatment (osimertinib) for people with advanced EGFR-mutant non-small cell lung cancer. The goal is to find the safest and most effective dose and to see how well the combination works. About 69 particip…

This study compares two treatments for people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation). One group gets the targeted drug osimertinib alone, the other gets osimertinib plus bevacizumab, which blocks blood vessel growth to tumors. The…

This early-phase trial is testing a new drug called PBF-1129 combined with the immunotherapy nivolumab in people with advanced non-small cell lung cancer that has returned or spread. The main goal is to find the safest dose and understand side effects. About 30 adults who have al…

This study tests a radiation method that targets the entire brain and spinal cord to kill cancer cells that have spread there, while avoiding a memory-related area called the hippocampus. It is for people with breast or lung cancer that has reached the fluid and tissues around th…

This early-stage trial tests the safety and best dose of gilteritinib, a drug already approved for leukemia, in 30 people with stage IV ALK-positive non-small cell lung cancer whose tumors stopped responding to other treatments. The goal is to see if the drug can control the canc…

This study tests a type of radiation therapy (craniospinal irradiation) for people with breast or lung cancer that has spread to the fluid and lining around the brain and spinal cord. The goal is to see if this treatment can help control the disease in the central nervous system.…

This study is for people with stage IV non-small cell lung cancer whose disease has gotten worse after immunotherapy. It tests a special type of radiation called grid therapy, which delivers high doses to small parts of the tumor, combined with standard immunotherapy. The goal is…

This study tests whether adding diclofenac, a common anti-inflammatory painkiller, can help control tumor growth in people with advanced lung cancer whose disease is starting to worsen on immunotherapy alone. About 20 adults with stage III or IV non-small cell lung cancer will re…

This study tests a combination of two drugs, sotorasib and trastuzumab deruxtecan, in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The goal is to see if the combination is safe, tolerable, and effective at shrinking tumors. About 37 adul…

This study compares two radiation treatments for people with small cell lung cancer that has spread to the brain. One treatment uses precise, high-dose radiation only on the tumors, while the other treats the whole brain but avoids the memory center. The goal is to see which appr…

This study tests whether adding ramucirumab to tepotinib works better than tepotinib alone for people with a certain type of advanced lung cancer (MET exon 14 skipping). Tepotinib blocks a faulty protein that makes cancer grow, while ramucirumab may cut off the tumor's blood supp…

This study tests whether adding the experimental drug iadademstat to standard immunotherapy (atezolizumab or durvalumab) can keep extensive-stage small cell lung cancer from growing longer than immunotherapy alone. About 45 adults whose cancer responded to initial chemoimmunother…

This study tests if a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) can help people with a specific genetic type of advanced lung cancer (LKB1-mutant) that has stopped responding to standard treatments. The trial will enroll 50 …

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors (like breast, lung, or skin cancer). The goal is to see if the combination is safe and helps the immune syst…

This study tests a new drug combination (GT103 plus pembrolizumab) for people with advanced non-small cell lung cancer that has a specific genetic change called STK11 mutation. The goal is to see if adding GT103 can help shrink tumors or slow the cancer's growth. About 28 adults …

This study tests whether adding SX-682 to the immunotherapy drug pembrolizumab helps shrink tumors in people with advanced non-small cell lung cancer that has spread or returned. About 30 adults whose tumors have a certain protein (PD-L1) will receive both drugs. The goal is to s…

This early-phase trial tests the safety and best dose of combining two drugs—vismodegib and atezolizumab—in people with advanced non-small cell lung cancer that has returned or spread. Vismodegib blocks certain enzymes that help cancer grow, while atezolizumab helps the immune sy…

This early-phase study tests whether combining two drugs, carfilzomib and sotorasib, is safe and effective for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. About 15 adults who have already tried a KRAS inhibitor will receive the combinat…

This early-phase study tests a combination of two drugs, osimertinib and tegavivint, as the first treatment for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC that has spread). The main goal is to find the safest dose and see how well the drugs work togeth…

This study tests a combination of chemotherapy (temozolomide) and immunotherapy (atezolizumab) as a second or third treatment option for people with small cell lung cancer that has spread or returned. The goal is to see if this combination can shrink tumors and help patients live…

This study tests a drug called avapritinib in people with advanced solid tumors that have spread and have specific gene changes (CKIT or PDGFRA mutations). The drug works by blocking enzymes that help cancer cells grow. The goal is to see if avapritinib can shrink or control thes…

This study tests if a precise type of proton radiation (pCSI) can help people with breast or lung cancer that has spread to the fluid-filled space around the brain and spinal cord live longer than standard x-ray radiation. About 115 participants will be randomly assigned to one o…

This study tests whether adding the immunotherapy drug cemiplimab to the standard two-drug combination (docetaxel and ramucirumab) can help people with advanced or recurrent non-small cell lung cancer live longer. Participants have already tried platinum-based chemotherapy and im…

This early-phase study tests a combination of two ways to give the immunotherapy drug nivolumab: through a vein and directly into the fluid around the spine. It is for people with melanoma or lung cancer that has spread to the lining of the brain or spinal cord (leptomeningeal di…

This study tests whether combining three targeted drugs (capmatinib, osimertinib, and ramucirumab) works better than two drugs alone for people with advanced non-small cell lung cancer that has specific EGFR and MET gene changes. The drugs block signals that help cancer grow and …

This study tests a dye called panitumumab-IRDye800 that attaches to lung cancer cells and makes them glow under a special camera during surgery. The goal is to help surgeons see and remove all cancer tissue more accurately. About 30 adults with lung cancer or lung metastases will…

This study compares two types of radiation therapy for people whose cancer has spread to the brain. One group gets a single high dose of radiation, while the other gets three smaller doses over several days. The goal is to see if the three-dose approach works better at controllin…

This study tests a smarter way to give radiation to people with lung cancer. Normally, the radiation plan is made before treatment starts, but tumors can shrink during treatment, which may expose healthy tissue to unnecessary radiation. In this study, the radiation plan is update…

This study is testing whether getting immunotherapy in the morning or the afternoon makes it work better for people with advanced or metastatic solid tumors like lung, kidney, or skin cancer. Researchers think the body's internal clock might affect how the immune system responds.…

This early-stage study tests whether giving palliative radiotherapy together with the drug lurbinectedin is safe for people with extensive-stage small cell lung cancer that has spread beyond the chest. The goal is to relieve symptoms caused by the cancer. About 22 adults whose ca…

This study tests whether a special yoga program can improve physical function, fatigue, sleep, and quality of life for people with lung or esophageal cancer who are getting radiation therapy, and also for their family caregivers. About 400 patient-caregiver pairs will take part. …

This study watches 800 people with advanced lung, pancreatic, or colorectal cancer to find different types of cancer-related weight and muscle loss (cachexia). Researchers hope to discover why some patients lose weight differently than others. The goal is to create better, more p…

This study looks at how often people with metastatic non-small cell lung cancer have trouble sleeping. Researchers will use a simple questionnaire to measure insomnia severity. The goal is to understand how common this sleep problem is in this group, which can help improve future…

This study looks at how immune cells called T cells change in people with advanced melanoma, lung cancer, or other solid tumors during anti-PD-1 treatment. Researchers will measure specific markers in blood samples to see if they can predict whether the therapy is working or if r…

This study tests whether a new screening tool can help people with advanced lung cancer better understand their disease and treatment options. About 100 patients will either use the tool or receive usual care. The goal is to see if the tool leads to more informed decisions that m…

This study looks at how PET/CT scans change during chemoimmunotherapy and radiation in people with stage IV non-small cell lung cancer. Researchers want to see if these scan changes can help predict how well the cancer responds to treatment. About 80 participants who have not yet…

This study looks at how biomarkers (like DNA in the blood) can help predict whether immunotherapy will work for people with advanced non-small cell lung cancer. Researchers will collect blood and tissue samples from about 535 participants to understand treatment response and find…

This study tests a conversation aid that helps lung cancer patients and their doctors make treatment decisions together. About 100 patients with advanced non-small cell lung cancer will use the tool during appointments to see if it improves shared decision-making and satisfaction…

This study looks at how the bacteria in your gut might influence stomach issues like diarrhea and colitis caused by certain cancer drugs (immune checkpoint inhibitors). Researchers will collect stool, blood, and tissue samples from 800 people with melanoma, lung cancer, or genito…

This study tests whether a portable device that creates electric fields is safe and practical for treating cancer that has spread to the lining of the spine. It includes up to 5 adults with breast or lung cancer that has spread to the spinal fluid and spine. The goal is to see if…